Seprafilm may be applied to many sites during ostomy creation.2,5

[IMAGE – Incidence of Incision Extension]

Midline and peristomal adhesions can complicate reversal of a colostomy or ileostomy.2 Additionally, bowel adhesions to the peristomal site following closure can cause adhesive small bowel obstruction.2 In a series of randomized controlled studies of patients receiving Seprafilm at primary radical colorectal resection, Seprafilm reduced midline and peristomal adhesions, therefore reducing the overall complexity including

  • Extension of peristomal incision2 
  • Operation time and blood loss2 
  • Inadvertent enterotomies and resulting bowel resection3

In one study, Seprafilm was shown to reduce the extent and severity of adhesions to the peristomal incision and therefore the need to extend the incision at ileostomy closure.2

Seprafilm application sites in ostomy creation1,5,6 

  • Ostomy site
  • Rectal stump
  • Omentum
  • Midline incision
  • Paracolic sidewall
  • Traumatized bowel

Indication
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

References

  1. Seprafilm Adhesion Barrier [package insert]. Cambridge, MA: Genzyme Biosurgery; 2008.
  2. Kusunoki M, Ikeuchi H, Yanagi H, et al. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today. 2005;35(11):940-945.
  3. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision: a prospective randomized trial. Dis Colon Rectum. 2003;46(9):1200-1207.
  4. Data on file, Genzyme Corp.
  5. Beck DE, Cohen Z, Fleshman JW, Kaufman HS, van Goor H, Wolff BG; for Adhesion Study Group Steering Committee. A prospective, randomized, multicenter, controlled study of the safety of Seprafilm® Adhesion Barrier in abdominopelvic surgery of the intestine. Dis Colon Rectum. 2003;46(10):1310-1319.
  6. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.

Clinical Benefits

Seprafilm has been studied in more than 4000 patients in 40 published clinical studies.16

Read more

Seprafilm placement video

Watch a demonstration of Seprafilm application in an ileostomy.

Watch video